Christopher Rovaldi, Chief Operating Officer at Keros Therapeutics, Inc. (KROS), sold 864 shares at $56.89 ($50K) on 2022-04-01, disclosed to the SEC on 2022-04-05.
Scheduled sale ($50k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.34 | 2 | $109 | 0.2% |
| 2 | $56.20 | 104 | $6K | 11.8% |
| 3 | $56.89 | 287 | $16K | 32.9% |
| 4 | $57.97 | 366 | $21K | 42.7% |
| 5 | $58.83 | 105 | $6K | 12.4% |
| Total | $57.49 avg | 864 |
| $50K |
| 100% |
| Filing → |
| XLRN | SELL | 2018-01-17 | $495K | — | Filing → |
| XLRN | SELL | 2018-01-04 | $157K | — | Filing → |
| XLRN | SELL | 2017-09-14 | $538K | — | Filing → |